drugset / Trial / NCT01124318
A Pilot Study of Lactofiltrum to Treat Atopic Dermatitis in Adults
Phase 2/3
Completed
90 enrolled
Avva Rus, JSC
Moscow Dermatovenerologic Clinical Dispensary № 1 · collabMoscow State University of Medicine and Dentistry · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose is to study efficacy of Lactofiltrum in adult patients with atopic dermatitis. Lactofiltrum consists of 85% of hidrolytic lignin and 15% of lactulose and acts as an enterosorbent, which enables to enhance metabolism and elimination of endotoxins and to normalize metabolic and immune processes. Additionally, lactulose stimulates Bifidobacterium flora and in aggregate it could improve skin condition afflicted by atopic dermatitis.
Timeline
- Start
- 2010-05
- Primary completion
- 2010-09
- Completion
- 2010-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Lactulose | Other / unclassified | — | Oral |
| Comparator | hydrolytic lignin | Unknown | — | Oral |